1
|
Karaghiannis V, Maric D, Garrec C, Maaziz N, Buffet A, Schmitt L, Antunes V, Airaud F, Aral B, Le Roy A, Corbineau S, Mansour-Hendili L, Lesieur V, Rimbert A, Laporte F, Delamare M, Rab M, Bézieau S, Cassinat B, Galacteros F, Gimenez-Roqueplo AP, Burnichon N, Cario H, Van Wijk R, Bento C, Girodon F, Hoogewijs D, Gardie B. Comprehensive in silico and functional studies for classification of EPAS1/HIF2A genetic variants identified in patients with erythrocytosis. Haematologica 2023. [PMID: 36700397 DOI: 10.3324/haematol.2022.281698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Indexed: 01/27/2023] Open
Abstract
Gain-of-function mutations in the EPAS1/HIF2A gene have been identified in patients with hereditary erythrocytosis that can be associated with the development of paraganglioma, pheochromocytoma and somatostatinoma. In the present study, we describe a unique european collection of 41 patients and 28 relatives diagnosed with an erythrocytosis associated with a germline genetic variant in EPAS1. In addition we identified 2 infants with severe erythrocytosis associated with a mosaic mutation present in less than 2% of the blood, one of whom later developed a paraganglioma. The aim of this study was to determine the causal role of these genetic variants, to establish pathogenicity, and to identify potential candidates eligible for the new HIF-222inhibitor treatment. Pathogenicity was predicted with in silico tools and the impact of 13 HIF-222variants has been studied by using canonical and real-time reporter luciferase assays. These functional assays consisted of a novel edited vector containing an expanded region of the erythropoietin (EPO) promoter combined with distal regulatory elements which substantially enhanced the HIF-22-dependent induction. Altogether, our studies allowed the classification of 11 mutations as pathogenic in 17 patients and 23 relatives. We described four new mutations (D525G, L526F, G527K, A530S) close to the key proline P531, which broadens the spectrum of mutations involved in erythrocytosis. Notably, we identified patients with only erythrocytosis associated with germline mutations A530S and Y532C previously identified at somatic state in tumors, thereby raising the complexity of the genotype/phenotype correlations. Altogether, this study allows accurate clinical follow-up of patients and opens the possibility of benefiting from HIF-222inhibitor treatment, so far the only targeted treatment in hypoxia-related erythrocytosis disease.
Collapse
Affiliation(s)
- Valéna Karaghiannis
- Ecole Pratique des Hautes Etudes, EPHE, Université PSL, France; Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes
| | - Darko Maric
- Section of Medicine, Department of Endocrinology, Metabolism and Cardiovascular System, University of Fribourg, CH-1700 Fribourg, Switzerland; National Center of Competence in Research "Kidney.CH"
| | - Céline Garrec
- Service de Génétique Médicale, CHU de Nantes, Nantes
| | - Nada Maaziz
- Service d'Hématologie Biologique, Pôle Biologie, CHU de Dijon, Dijon
| | - Alexandre Buffet
- Université Paris Cité, Inserm, PARCC, F-75015 Paris, France; Département de Médecine Génomique des Tumeurs et des Cancers, AP-HP, Hôpital européen Georges Pompidou, F-75015 Paris
| | - Loïc Schmitt
- Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes
| | - Vincent Antunes
- Section of Medicine, Department of Endocrinology, Metabolism and Cardiovascular System, University of Fribourg, CH-1700 Fribourg, Switzerland; National Center of Competence in Research "Kidney.CH"
| | | | - Bernard Aral
- Service d'Hématologie Biologique, Pôle Biologie, CHU de Dijon, Dijon
| | - Amandine Le Roy
- Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes
| | | | - Lamisse Mansour-Hendili
- Département de Biochimie-Biologie Moléculaire, Pharmacologie, Génétique Médicale, APHP, Hôpitaux Universitaires Henri Mondor, Créteil, France; Université Paris-Est Créteil, IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex, Créteil
| | - Valentine Lesieur
- Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes
| | - Antoine Rimbert
- Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes
| | - Fabien Laporte
- Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes
| | - Marine Delamare
- Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes
| | - Minke Rab
- Central Diagnostic Laboratory - Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht
| | - Stéphane Bézieau
- Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France; Service de Génétique Médicale, CHU de Nantes, Nantes
| | - Bruno Cassinat
- Université Paris Cité, APHP, Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, Paris
| | - Frédéric Galacteros
- Université Paris-Est Créteil, IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex, Créteil, France; Red Cell Disease Referral Center-UMGGR, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil
| | - Anne-Paule Gimenez-Roqueplo
- Université Paris Cité, Inserm, PARCC, F-75015 Paris, France; Département de Médecine Génomique des Tumeurs et des Cancers, AP-HP, Hôpital européen Georges Pompidou, F-75015 Paris
| | - Nelly Burnichon
- Université Paris Cité, Inserm, PARCC, F-75015 Paris, France; Département de Médecine Génomique des Tumeurs et des Cancers, AP-HP, Hôpital européen Georges Pompidou, F-75015 Paris
| | - Holger Cario
- Department of Pediatrics and Adolescent Medicine, University Medical Center, Ulm
| | - Richard Van Wijk
- Central Diagnostic Laboratory - Research, University Medical Center Utrecht, Utrecht University, Utrecht
| | - Celeste Bento
- Hematology Department, Centro Hospitalar e Universitário de Coimbra; CIAS, University of Coimbra
| | - François Girodon
- Service d'Hématologie Biologique, Pôle Biologie, CHU de Dijon, Dijon, France; Inserm U1231, Université de Bourgogne, Dijon, France; Laboratoire d'Excellence GR-Ex
| | - David Hoogewijs
- Section of Medicine, Department of Endocrinology, Metabolism and Cardiovascular System, University of Fribourg, CH-1700 Fribourg, Switzerland; National Center of Competence in Research "Kidney.CH"
| | - Betty Gardie
- Ecole Pratique des Hautes Etudes, EPHE, Université PSL, France; Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France; Laboratoire d'Excellence GR-Ex
| |
Collapse
|
2
|
Corbineau S, Lassalle B, Givelet M, Souissi-Sarahoui I, Firlej V, Romeo PH, Allemand I, Riou L, Fouchet P. Spermatogonial stem cells and progenitors are refractory to reprogramming to pluripotency by the transcription factors Oct3/4, c-Myc, Sox2 and Klf4. Oncotarget 2018; 8:10050-10063. [PMID: 28052023 PMCID: PMC5354640 DOI: 10.18632/oncotarget.14327] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Accepted: 11/30/2016] [Indexed: 12/25/2022] Open
Abstract
The male germinal lineage, which is defined as unipotent, produces sperm through spermatogenesis. However, embryonic primordial germ cells and postnatal spermatogonial stem cells (SSCs) can change their fate and convert to pluripotency in culture when they are not controlled by the testicular microenvironment. The mechanisms underlying these reprogramming processes are poorly understood. Testicular germ cell tumors, including teratoma, share some molecular characteristics with pluripotent cells, suggesting that cancer could result from an abnormal differentiation of primordial germ cells or from an abnormal conversion of SCCs to pluripotency in the testis. Here, we investigated whether the somatic reprogramming factors Oct3/4, Sox2, Klf4 and c-Myc (OSKM) could play a role in SSCs reprogramming and induce pluripotency using a doxycycline-inducible transgenic Col1a1-4F2A-OSKM mouse model. We showed that, in contrast to somatic cells, SSCs from adult mice are resistant to this reprogramming strategy, even in combination with small molecules, hypoxia, or p53 deficiency, which were previously described to favour the conversion of somatic cells to pluripotency. This finding suggests that adult SSCs have developed specific mechanisms to repress reprogramming by OSKM factors, contributing to circumvent testicular cancer initiation events.
Collapse
Affiliation(s)
- Sébastien Corbineau
- CEA DRF iRCM SCSR, Laboratoire de Recherche sur la réparation et la Transcription dans les cellules Souches, UMR 967, F-92265 Fontenay-aux-Roses, France.,INSERM, UMR967, F-92265 Fontenay-aux-Roses, France.,Université Paris Diderot, Sorbonne Paris Cité, UMR 967, F-92265 Fontenay-aux-Roses, France.,Université Paris Sud, UMR 967, F-92265 Fontenay-aux-Roses, France
| | - Bruno Lassalle
- CEA DRF iRCM SCSR, Laboratoire de Recherche sur la réparation et la Transcription dans les cellules Souches, UMR 967, F-92265 Fontenay-aux-Roses, France.,INSERM, UMR967, F-92265 Fontenay-aux-Roses, France.,Université Paris Diderot, Sorbonne Paris Cité, UMR 967, F-92265 Fontenay-aux-Roses, France.,Université Paris Sud, UMR 967, F-92265 Fontenay-aux-Roses, France
| | - Maelle Givelet
- CEA DRF iRCM SCSR, Laboratoire de Recherche sur la réparation et la Transcription dans les cellules Souches, UMR 967, F-92265 Fontenay-aux-Roses, France.,INSERM, UMR967, F-92265 Fontenay-aux-Roses, France.,Université Paris Diderot, Sorbonne Paris Cité, UMR 967, F-92265 Fontenay-aux-Roses, France.,Université Paris Sud, UMR 967, F-92265 Fontenay-aux-Roses, France.,INSERM U1016, Institut Cochin, Paris 75014, France.,CNRS UMR8104, Paris 75014, France.,Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris 75014, France
| | - Inès Souissi-Sarahoui
- INSERM, UMR967, F-92265 Fontenay-aux-Roses, France.,Université Paris Diderot, Sorbonne Paris Cité, UMR 967, F-92265 Fontenay-aux-Roses, France.,Université Paris Sud, UMR 967, F-92265 Fontenay-aux-Roses, France.,CEA DRF iRCM SCSR, Laboratoire de Radiopathologie, UMR 967, F-92265 Fontenay-aux-Roses, France
| | - Virginie Firlej
- CEA DRF iRCM SCSR, Laboratoire de Recherche sur la réparation et la Transcription dans les cellules Souches, UMR 967, F-92265 Fontenay-aux-Roses, France.,INSERM, UMR967, F-92265 Fontenay-aux-Roses, France.,Université Paris Diderot, Sorbonne Paris Cité, UMR 967, F-92265 Fontenay-aux-Roses, France.,Université Paris Sud, UMR 967, F-92265 Fontenay-aux-Roses, France
| | - Paul Henri Romeo
- CEA DRF iRCM SCSR, Laboratoire de Recherche sur la réparation et la Transcription dans les cellules Souches, UMR 967, F-92265 Fontenay-aux-Roses, France.,INSERM, UMR967, F-92265 Fontenay-aux-Roses, France.,Université Paris Diderot, Sorbonne Paris Cité, UMR 967, F-92265 Fontenay-aux-Roses, France.,Université Paris Sud, UMR 967, F-92265 Fontenay-aux-Roses, France
| | - Isabelle Allemand
- CEA DRF iRCM SCSR, Laboratoire de Gamétogenèse, Apoptose et Génotoxicité, UMR 967, F-92265 Fontenay-aux-Roses, France
| | - Lydia Riou
- CEA DRF iRCM SCSR, Laboratoire de Recherche sur la réparation et la Transcription dans les cellules Souches, UMR 967, F-92265 Fontenay-aux-Roses, France.,INSERM, UMR967, F-92265 Fontenay-aux-Roses, France.,Université Paris Diderot, Sorbonne Paris Cité, UMR 967, F-92265 Fontenay-aux-Roses, France.,Université Paris Sud, UMR 967, F-92265 Fontenay-aux-Roses, France
| | - Pierre Fouchet
- CEA DRF iRCM SCSR, Laboratoire de Recherche sur la réparation et la Transcription dans les cellules Souches, UMR 967, F-92265 Fontenay-aux-Roses, France.,INSERM, UMR967, F-92265 Fontenay-aux-Roses, France.,Université Paris Diderot, Sorbonne Paris Cité, UMR 967, F-92265 Fontenay-aux-Roses, France.,Université Paris Sud, UMR 967, F-92265 Fontenay-aux-Roses, France
| |
Collapse
|
3
|
Yang G, Si-Tayeb K, Corbineau S, Vernet R, Gayon R, Dianat N, Martinet C, Clay D, Goulinet-Mainot S, Tachdjian G, Tachdjian G, Burks D, Vallier L, Bouillé P, Dubart-Kupperschmitt A, Weber A. Integration-deficient lentivectors: an effective strategy to purify and differentiate human embryonic stem cell-derived hepatic progenitors. BMC Biol 2013; 11:86. [PMID: 23870169 PMCID: PMC3751548 DOI: 10.1186/1741-7007-11-86] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2013] [Accepted: 07/10/2013] [Indexed: 01/11/2023] Open
Abstract
Background Human pluripotent stem cells (hPSCs) hold great promise for applications in regenerative medicine. However, the safety of cell therapy using differentiated hPSC derivatives must be improved through methods that will permit the transplantation of homogenous populations of a specific cell type. To date, purification of progenitors and mature cells generated from either embryonic or induced pluripotent stem cells remains challenging with use of conventional methods. Results We used lentivectors encoding green fluorescent protein (GFP) driven by the liver-specific apoliprotein A-II (APOA-II) promoter to purify human hepatic progenitors. We evaluated both integrating and integration-defective lentivectors in combination with an HIV integrase inhibitor. A human embryonic stem cell line was differentiated into hepatic progenitors using a chemically defined protocol. Subsequently, cells were transduced and sorted at day 16 of differentiation to obtain a cell population enriched in hepatic progenitor cells. After sorting, more than 99% of these APOA-II-GFP-positive cells expressed hepatoblast markers such as α-fetoprotein and cytokeratin 19. When further cultured for 16 days, these cells underwent differentiation into more mature cells and exhibited hepatocyte properties such as albumin secretion. Moreover, they were devoid of vector DNA integration. Conclusions We have developed an effective strategy to purify human hepatic cells from cultures of differentiating hPSCs, producing a novel tool that could be used not only for cell therapy but also for in vitro applications such as drug screening. The present strategy should also be suitable for the purification of a broad range of cell types derived from either pluripotent or adult stem cells.
Collapse
Affiliation(s)
- Guanghua Yang
- INSERM U 972, IFR 93, Bicêtre Hospital, and Paul Brousse Hospital, Villejuif F-94807, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Touboul T, Hannan NRF, Corbineau S, Martinez A, Martinet C, Branchereau S, Mainot S, Strick-Marchand H, Pedersen R, Di Santo J, Weber A, Vallier L. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 2010; 51:1754-65. [PMID: 20301097 DOI: 10.1002/hep.23506] [Citation(s) in RCA: 359] [Impact Index Per Article: 25.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
UNLABELLED Generation of hepatocytes from human embryonic stem cells (hESCs) could represent an advantageous source of cells for cell therapy approaches as an alternative to orthotopic liver transplantation. However, the generation of differentiated hepatocytes from hESCs remains a major challenge, especially using a method compatible with clinical applications. We report a novel approach to differentiate hESCs into functional hepatic cells using fully defined culture conditions, which recapitulate essential stages of liver development. hESCs were first differentiated into a homogenous population of endoderm cells using a combination of activin, fibroblast growth factor 2, and bone morphogenetic protein 4 together with phosphoinositide 3-kinase inhibition. The endoderm cells were then induced to differentiate further into hepatic progenitors using fibroblast growth factor 10, retinoic acid, and an inhibitor of activin/nodal receptor. After further maturation, these cells expressed markers of mature hepatocytes, including asialoglycoprotein receptor, tyrosine aminotransferase, alpha1-antitrypsin, Cyp7A1, and hepatic transcription factors such as hepatocyte nuclear factors 4alpha and 6. Furthermore, the cells generated under these conditions exhibited hepatic functions in vitro, including glycogen storage, cytochrome activity, and low-density lipoprotein uptake. After transduction with a green fluorescent protein-expressing lentivector and transplantation into immunodeficient uPA transgenic mice, differentiated cells engrafted into the liver, grew, and expressed human albumin and alpha1-antitrypsin as well as green fluorescent protein for at least 8 weeks. In addition, we showed that hepatic cells could be generated from human-induced pluripotent cells derived from reprogrammed fibroblasts, demonstrating the efficacy of this approach with pluripotent stem cells of diverse origins. CONCLUSION We have developed a robust and efficient method to differentiate pluripotent stem cells into hepatic cells, which exhibit characteristics of human hepatocytes. Our approach should facilitate the development of clinical grade hepatocytes for transplantation and for research on drug discovery.
Collapse
Affiliation(s)
- Thomas Touboul
- Institut National de la Santé et de la Recherche Médicale, INSERM, Unite 972, IFR 93, Bicêtre Hospital, Kremlin-Bicêtre, France. [corrected]
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Ausseil J, Desmaris N, Bigou S, Attali R, Corbineau S, Vitry S, Parent M, Cheillan D, Fuller M, Maire I, Vanier MT, Heard JM. Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One 2008; 3:e2296. [PMID: 18509511 PMCID: PMC2396504 DOI: 10.1371/journal.pone.0002296] [Citation(s) in RCA: 98] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2008] [Accepted: 04/16/2008] [Indexed: 01/11/2023] Open
Abstract
Background In mucopolysaccharidosis type IIIB, a lysosomal storage disease causing early onset mental retardation in children, the production of abnormal oligosaccharidic fragments of heparan sulfate is associated with severe neuropathology and chronic brain inflammation. We addressed causative links between the biochemical, pathological and inflammatory disorders in a mouse model of this disease. Methodology/Principal Findings In cell culture, heparan sulfate oligosaccharides activated microglial cells by signaling through the Toll-like receptor 4 and the adaptor protein MyD88. CD11b positive microglial cells and three-fold increased expression of mRNAs coding for the chemokine MIP1α were observed at 10 days in the brain cortex of MPSIIIB mice, but not in MPSIIIB mice deleted for the expression of Toll-like receptor 4 or the adaptor protein MyD88, indicating early priming of microglial cells by heparan sulfate oligosaccharides in the MPSIIIB mouse brain. Whereas the onset of brain inflammation was delayed for several months in doubly mutant versus MPSIIIB mice, the onset of disease markers expression was unchanged, indicating similar progression of the neurodegenerative process in the absence of microglial cell priming by heparan sulfate oligosaccharides. In contrast to younger mice, inflammation in aged MPSIIIB mice was not affected by TLR4/MyD88 deficiency. Conclusions/Significance These results indicate priming of microglia by HS oligosaccharides through the TLR4/MyD88 pathway. Although intrinsic to the disease, this phenomenon is not a major determinant of the neurodegenerative process. Inflammation may still contribute to neurodegeneration in late stages of the disease, albeit independent of TLR4/MyD88. The results support the view that neurodegeneration is primarily cell autonomous in this pediatric disease.
Collapse
Affiliation(s)
- Jérôme Ausseil
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | - Nathalie Desmaris
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | - Stéphanie Bigou
- Service de Neurologie Pédiatrique, Hôpital Bicêtre, Assistance Publique/Hôpitaux de Paris, INSERM U802, 94000, le Kremlin-Bicêtre, France
| | - Ruben Attali
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | - Sébastien Corbineau
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | - Sandrine Vitry
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | - Mathieu Parent
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | | | - Maria Fuller
- Genetic Medicine, Children, Youth and Women's Health Service, North Adelaïde, Australia
| | - Irène Maire
- Groupement hospitalier est, CBPE, Bron, France
| | | | - Jean-Michel Heard
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
- * E-mail:
| |
Collapse
|